Isabelle Madelaine
Overview
Explore the profile of Isabelle Madelaine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
521
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Remond M, Pachev A, Battistella M, Gandon C, Mourah S, Madelaine I, et al.
Ther Adv Med Oncol
. 2024 Sep;
16:17588359241280541.
PMID: 39314916
Malignant PEComas are an extremely rare subtype of soft tissue sarcomas. Here, we report the case of a man presenting with a perirectal PEComa and liver metastasis. Since the tumor...
2.
Castilla-Llorente C, Bonnin A, Lansiaux P, Tudesq J, Beuvon C, Fabreguettes J, et al.
Bull Cancer
. 2024 Sep;
112(1S):S36-S53.
PMID: 39242251
First-line treatments of autoimmune systemic diseases (ARD) are based on the use of various types of immunosuppressive or immunomodulatory drugs, either alone or in association, according to standardized reference protocols....
3.
Fere-Gely L, Deville L, Peyron I, Trevisan L, Mackowiak V, Dancoine X, et al.
Ann Pharm Fr
. 2024 Apr;
82(5):937-943.
PMID: 38688435
Ensuring the safety of patient medication management is a public health priority. In hospitals, the medication circuit involves risks, especially in terms of storage. As part of an institutional project,...
4.
Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, et al.
BioDrugs
. 2024 Apr;
38(3):465-475.
PMID: 38643301
Background: An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs. Objective: This...
5.
[Reform of early access program in France: Impact on workload in a pharmacy and risk identification]
Jouhet O, Demir J, Sitbon M, Bildan M, Bros A, Kim E, et al.
Ann Pharm Fr
. 2024 Feb;
82(4):727-738.
PMID: 38408723
The reform of derogatory access authorisations (DAs) on 1st July 2021 has distorted the routine of the hospital pharmacists dealing with innovative medicines that are waiting for marketing authorization or...
6.
Ranchon F, Chatelut E, Lambert J, Sesques P, Thibault C, Madelaine I, et al.
Bull Cancer
. 2023 Oct;
110(12):1343-1351.
PMID: 37827964
Antibody Drug Conjugates (ADC) and bispecific antibodies are booming and were the subject of the scientific event proposed by the French Society of Oncological Pharmacy, October 13, 2022. An ADC...
7.
Marchal M, Robert M, Pesque R, Jourdan N, Sessink P, Madelaine I, et al.
J Oncol Pharm Pract
. 2023 May;
30(2):278-285.
PMID: 37254519
Introduction: During administration of chemotherapies, disconnection presents risks for nurses. Thus, it is recommended to flush the infusion line with solvent to reduce this risk and ensure that the entire...
8.
Slimano F, Tournamille J, Bardin C, Madelaine I, Hulin C, Moreau P, et al.
Bull Cancer
. 2023 May;
110(6):731-733.
PMID: 37225617
No abstract available.
9.
Pieragostini R, Xhaard A, Sauvageon H, Madelaine I, Touratier S, Denis B
Med Mycol
. 2023 Mar;
61(4).
PMID: 36963767
To describe reasons for initiation and evolution under isavuconazole (ISZ), a 2-year prospective and observational study was performed. Anonymized data collected during the first 3 months of treatment were indications...
10.
Ta V, Battistella M, Zhao L, Dobos G, Ram-Wolff C, Madelaine I, et al.
J Invest Dermatol
. 2023 Jan;
143(7):1329-1332.e3.
PMID: 36716922
No abstract available.